Heat shock proteins and cancer: How can nanomedicine be harnessed?

Journal of Controlled Release

Volumn 248, Issue , 2017, Pages 133-143

  Sauvage, Félix ^a   Messaoudi, Samir ^b   Fattal, Elias ^a   Barratt, Gillian ^a   Vergnaud Gauduchon, Juliette ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ PARIS SUD   (France)

Author keywords

Drug delivery; hsp90 inhibition; Hyperthermia; Nanomedicine; Stress response

Indexed keywords

CELL MEMBRANES; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; DRUG DELIVERY; MACHINERY; MEDICAL NANOTECHNOLOGY; ONCOLOGY; TARGETED DRUG DELIVERY;

ACTIVE MOLECULES; ENDOPLASMIC RETICULUM; HEAT SHOCK PROTEIN; HYPERTHERMIA; INTRACELLULAR COMPARTMENTS; POOR SOLUBILITIES; POTENTIAL INHIBITORS; STRESS RESPONSE;

PROTEINS;

ANTINEOPLASTIC AGENT; CHAPERONE; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NANOCARRIER; NANOPARTICLE; WATER; DRUG CARRIER; HEAT SHOCK PROTEIN;

CANCER CHEMOTHERAPY; CANCER THERAPY; CELL MEMBRANE; CYTOSOL; DRUG DELIVERY SYSTEM; ENDOPLASMIC RETICULUM; HUMAN; MALIGNANT NEOPLASM; MITOCHONDRION; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN TARGETING; REVIEW; SOLUBILITY; TARGET CELL; THERMOTHERAPY; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 85010015833     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.01.013     Document Type: Review

References (125)

1. [1] Neckers, L., Heat shock protein 90: the cancer chaperone. Calderwood, S.K., Sherman, M.Y., Ciocca, D.R., (eds.) Heat Shock Proteins in Cancer Heat Shock Proteins, 2007, Springer, Netherlands, 231–252.
2. [2] Meyer, P., Prodromou, C., Liao, C., Hu, B., Mark Roe, S., Vaughan, C.K., Vlasic, I., Panaretou, B., Piper, P.W., Pearl, L.H., Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 23:3 (2004), 511–519.
3. [3] Street, T.O., Lavery, L.A., Agard, D.A., Substrate binding drives large-scale conformational changes in the Hsp90 molecular chaperone. Mol. Cell 42:1 (2011), 96–105.
4. [4] Tarone, G., Brancaccio, M., Keep your heart in shape: molecular chaperone networks for treating heart disease. Cardiovasc. Res. 102:3 (2014), 346–361.
5. [5] Calderwood, S.K., Molecular cochaperones: tumor growth and cancer treatment. Scientifica, 2013, 2013, e217513.
6. [6] Pearl, L., Review, H., The HSP90 molecular chaperone-an enigmatic ATPase. Biopolymers 105:8 (2016), 594–607.
7. [7] Calderwood, S.K., Cdc37 as a Co-Chaperone to Hsp90. 2015, Springer International Publishing, 103–112.
8. [8] Rehn, A.B., Buchner, J., p23 and Aha1. 2015, Springer International Publishing, 113–131.
9. [9] Nakai, A., Regulation of HSF activation and repression. Takaki, E., Nakai, A., (eds.) Heat Shock Factor, 2016, Springer, Japan, 51–72.
10. [10] Shamovsky, I., Nudler, E., New insights into the mechanism of heat shock response activation. Cell. Mol. Life Sci. 65:6 (2008), 855–861.
11. [11] Shi, Y., Mosser, D.D., Morimoto, R.I., Molecularchaperones as HSF1-specific transcriptional repressors. Genes Dev. 12:5 (1998), 654–666.
12. [12] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
13. [13] Garg, G., Khandelwal, A., Blagg, B.S.J., Anticancer inhibitors of Hsp90 function: beyond the usual suspects. Adv. Cancer Res. 129 (2016), 51–88.
14. [14] Barrott, J.J., Haystead, T.A.J., Hsp90, an unlikely ally in the war on cancer. FEBS J. 280:6 (2013), 1381–1396.
15. [15] Zhang, L., Shen, A., Wang, L., Liu, H., Chen, D., Xiong, B., Shen, J., Geng, M., FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells. Oncoscience 2:4 (2015), 419–427.
16. [16] Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz, L.C., Burrows, F.J., A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:6956 (2003), 407–410.
17. [17] Chiosis, G., Neckers, L., Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. Biol. 1:5 (2006), 279–284.
18. [18] Roe, S.M., Prodromou, C., O'Brien, R., Ladbury, J.E., Piper, P.W., Pearl, L.H., Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42:2 (1999), 260–266.
19. [19] Schulte, T.W., Akinaga, S., Soga, S., Sullivan, W., Stensgard, B., Toft, D., Neckers, L.M., Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 3:2 (1998), 100–108.
20. [20] Samuni, Y., Ishii, H., Hyodo, F., Samuni, U., Krishna, M.C., Goldstein, S., Mitchell, J.B., Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Free Radic. Biol. Med. 48:11 (2010), 1559–1563.
21. [21] Supko, J.G., Hickman, R.L., Grever, M.R., Malspeis, L., Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36:4 (1995), 305–315.
22. [22] Rastelli, G., Tian, Z.-Q., Wang, Z., Myles, D., Liu, Y., Structure-based design of 7-carbamate analogs of geldanamycin. Bioorg. Med. Chem. Lett. 15:22 (2005), 5016–5021.
23. [23] Chiosis, G., Lucas, B., Shtil, A., Huezo, H., Rosen, N., Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10:11 (2002), 3555–3564.
24. [24] Marcu, M.G., Chadli, A., Bouhouche, I., Catelli, M., Neckers, L.M., The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275:47 (2000), 37181–37186.
25. [25] Gunaherath, G.M.K.B., Marron, M.T., Wijeratne, E.M.K., Whitesell, L., Gunatilaka, A.A.L., Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors. Bioorg. Med. Chem. 21:17 (2013), 5118–5129.
26. [26] Le Bras, G., Radanyi, C., Peyrat, J.-F., Brion, J.-D., Alami, M., Marsaud, V., Stella, B., Renoir, J.-M., New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J. Med. Chem. 50:24 (2007), 6189–6200.
27. [27] Yu, X.M., Shen, G., Neckers, L., Blake, H., Holzbeierlein, J., Cronk, B., Blagg, B.S.J., Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 127:37 (2005), 12778–12779.
28. [28] Donnelly, A., Blagg, B.S.J., Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15:26 (2008), 2702–2717.
29. [29] Audisio, D., Methy-Gonnot, D., Radanyi, C., Renoir, J.-M., Denis, S., Sauvage, F., Vergnaud-Gauduchon, J., Brion, J.-D., Messaoudi, S., Alami, M., Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors. Eur. J. Med. Chem. 83 (2014), 498–507.
30. [30] Audisio, D., Messaoudi, S., Cegielkowski, L., Peyrat, J.-F., Brion, J.-D., Methy-Gonnot, D., Radanyi, C., Renoir, J.-M., Alami, M., Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery. ChemMedChem 6:5 (2011), 804–815.
31. [31] McAlpine, S., Targeting the C-terminus of Hsp90 as a cancer therapy. McConnell, J., Wang, Y., McAlpine, S.R., Edkins, A.L., (eds.) Heat Shock Protein Inhibitors Topics in Medicinal Chemistry, 2015, Springer International Publishing, 1–20.
32. [32] Wang, Y., McAlpine, S.R., C-terminal heat shock protein 90 modulators produce desirable oncogenic properties. Org. Biomol. Chem. 13:16 (2015), 4627–4631.
33. [33] Zhao, Z., Zhu, J., Quan, H., Wang, G., Li, B., Zhu, W., Xie, C., Lou, L., × 66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response. Oncotarget, 2016.
34. [34] Hillaireau, H., Couvreur, P., Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66:17 (2009), 2873–2896.
35. [35] Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65:1–2 (2000), 271–284.
36. [36] Nichols, J.W., Bae, Y.H., EPR: evidence and fallacy. J. Control. Release 190 (2014), 451–464.
37. [37] Alshaer, W., Hillaireau, H., Vergnaud, J., Ismail, S., Fattal, E., Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjug. Chem., 2014.
38. [38] Nascimento, T.L., Hillaireau, H., Vergnaud, J., Fattal, E., Lipid-based Nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and unmet needs. Nanomedicine 11:14 (2016), 1865–1887.
39. [39] Ding, H., Sagar, V., Agudelo, M., Pilakka-Kanthikeel, S., Atluri, V.S.R., Raymond, A., Samikkannu, T., Nair, M.P., Enhanced blood–brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome Nanoformulation. Nanotechnology, 25(5), 2014, 55101.
40. [40] Sauvage, F., Barratt, G., Herfindal, L., Vergnaud-Gauduchon, J., The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status. Curr. Pharm. Biotechnol. 17:1 (2016), 30–41.
41. [41] Xiong, M.P., Yáñez, J.A., Remsberg, C.M., Ohgami, Y., Kwon, G.S., Davies, N.M., Forrest, M.L., Formulation of a geldanamycin prodrug in mPEG-B-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J. Control. Release 129:1 (2008), 33–40.
42. [42] Forrest, M.L., Zhao, A., Won, C.-Y., Malick, A.W., Kwon, G.S., Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-B-poly(epsilon-caprolactone) micelles. J. Control. Release 116:2 (2006), 139–149.
43. [43] Tham, E.H., Cheng, Y.K., Tay, M.H., Alcasabas, A.P., Shek, L.P.-C., Evaluation and management of hypersensitivity reactions to chemotherapy agents. Postgrad. Med. J., 2015 (postgradmedj-2014-132686).
44. [44] Mendelson, D., Saif, M.W., Erlichman, C., Dragovich, T., Gordon, M., Toft, C.D., Timony, G., Burrows, F., Padgett, C., De Jager, R.L., Von Hoff, D., Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. AACR Meet. Abstr., 2006(1), 2006, 683-b.
45. [45] Tao, C., Yu, C., De, T.K., Everett, N., Frankel, T., Ci, S., Trieu, V., Soon-Shiong, P., Desai, N., Preparation of nanoparticle albumin bound 17AAG (Nab-17AAG) suitable for intravenous administration. AACR Meet. Abstr., 2005(1), 2005, 336-b.
46. [46] A trial of ABI-010 & ABI-007 in patients with advanced non-hematologic malignancies—full text view—ClinicalTrials.Gov. http://www.clinicaltrials.gov/ct2/show/NCT00820768?term=ABI-010&rank=1 (accessed Apr 17, 2016).
47. [47] Saxena, V., Naguib, Y., Hussain, M.D., Folate receptor targeted 17-Allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer. Colloids Surf. B: Biointerfaces 94 (2012), 274–280.
48. [48] Raja, S.M., Desale, S.S., Mohapatra, B., Luan, H., Soni, K., Zhang, J., Storck, M.A., Feng, D., Bielecki, T.A., Band, V., Cohen, S.M., Bronich, T.K., Band, H., Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget 7:9 (2016), 10522–10535.
49. [49] Liu, K.-S., Liu, H., Qi, J.-H., Liu, Q.-Y., Liu, Z., Xia, M., Xing, G.-W., Wang, S.-X., Wang, Y.-F., SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett. 318:2 (2012), 180–188.
50. [50] Okawa, Y., Hideshima, T., Steed, P., Vallet, S., Hall, S., Huang, K., Rice, J., Barabasz, A., Foley, B., Ikeda, H., Raje, N., Kiziltepe, T., Yasui, H., Enatsu, S., Anderson, K.C., SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and Osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113:4 (2009), 846–855.
51. [51] Wang, S.-X., Ju, H.-Q., Liu, K.-S., Zhang, J.-X., Wang, X., Xiang, Y.-F., Wang, R., Liu, J.-Y., Liu, Q.-Y., Xia, M., Xing, G.-W., Liu, Z., Wang, Y.-F., SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Biosci. Biotechnol. Biochem. 75:8 (2011), 1540–1545.
52. [52] Dong, D., Wang, X., Wang, H., Zhang, X., Wang, Y., Wu, B., Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112. Int. J. Nanomedicine 10 (2015), 2521–2535.
53. [53] Sauvage, F., Franzè, S., Bruneau, A., Alami, M., Denis, S., Nicolas, V., Lesieur, S., Legrand, F.-X., Barratt, G., Messaoudi, S., Vergnaud-Gauduchon, J., Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells. Int. J. Pharm. 499:1–2 (2016), 101–109.
54. [54] Pore, S.K., Choudhary, A., Rathore, B., Ganguly, A., Sujitha, P., Ganesh Kumar, C., Agawane, S.B., Kumar, J.M., Scaria, V., Pillai, B., Banerjee, R., Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect. Biomaterials 34:28 (2013), 6804–6817.
55. [55] Xiong, M.P., Yáñez, J.A., Kwon, G.S., Davies, N.M., Forrest, M.L., A Cremophor-free formulation for Tanespimycin (17-AAG) using PEO-B-PDLLA micelles: characterization and pharmacokinetics in rats. J. Pharm. Sci. 98:4 (2009), 1577–1586.
56. [56] Chandran, T., Katragadda, U., Teng, Q., Tan, C., Design and evaluation of micellar nanocarriers for 17-Allyamino-17-demethoxygeldanamycin (17-AAG). Int. J. Pharm. 392:1–2 (2010), 170–177.
57. [57] Saxena, V., Hussain, M.D., Formulation and in vitro evaluation of 17-Allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma Multiforme. Colloids Surf. B: Biointerfaces 112 (2013), 350–355.
58. [58] Larson, N., Greish, K., Bauer, H., Maeda, H., Ghandehari, H., Synthesis and evaluation of poly(styrene-Co-maleic acid) micellar nanocarriers for the delivery of Tanespimycin. Int. J. Pharm. 420:1 (2011), 111–117.
59. [59] Saif, M.W., Erlichman, C., Dragovich, T., Mendelson, D., Toft, D., Burrows, F., Storgard, C., Von Hoff, D., Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(Allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother. Pharmacol. 71:5 (2013), 1345–1355.
60. [60] Won, Y.-W., Yoon, S.-M., Sonn, C.H., Lee, K.-M., Kim, Y.-H., Nano self-assembly of recombinant human gelatin conjugated with α-Tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery. ACS Nano 5:5 (2011), 3839–3848.
61. [61] Yang, R., Tang, Q., Miao, F., An, Y., Li, M., Han, Y., Wang, X., Wang, J., Liu, P., Chen, R., Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice. Int. J. Nanomedicine 10 (2015), 7345–7358.
62. [62] Önyüksel, H., Mohanty, P.S., Rubinstein, I., VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int. J. Pharm. 365:1–2 (2009), 157–161.
63. [63] Lin, T.-Y., Guo, W., Long, Q., Ma, A., Liu, Q., Zhang, H., Huang, Y., Chandrasekaran, S., Pan, C., Lam, K.S., Li, Y., HSP90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy. Theranostics 6:9 (2016), 1324–1335.
64. [64] Rochani, A.K., Balasubramanian, S., Ravindran Girija, A., Raveendran, S., Borah, A., Nagaoka, Y., Nakajima, Y., Maekawa, T., Kumar, D.S., Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation. Int. J. Pharm. 511:1 (2016), 648–658.
65. [65] Hasenstein, J.R., Shin, H.-C., Kasmerchak, K., Buehler, D., Kwon, G.S., Kozak, K.R., Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-AAG. Mol. Cancer Ther. 11:10 (2012), 2233–2242.
66. [66] Tomoda, K., Tam, Y.T., Cho, H., Buehler, D., Kozak, K.R., Kwon, G.S., Triolimus: a multi-drug loaded polymeric micelle containing paclitaxel, 17-AAG, and rapamycin as a novel radiosensitizer. Macromol. Biosci., 2016.
67. [67] Katragadda, U., Teng, Q., Rayaprolu, B.M., Chandran, T., Tan, C., Multi-drug delivery to tumor cells via micellar nanocarriers. Int. J. Pharm. 419:1–2 (2011), 281–286.
68. [68] Pradhan, R., Ramasamy, T., Choi, J.Y., Kim, J.H., Poudel, B.K., Tak, J.W., Nukolova, N., Choi, H.-G., Yong, C.S., Kim, J.O., Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and Tanespimycin. Carbohydr. Polym. 123 (2015), 313–323.
69. [69] Desale, S.S., Raja, S.M., Kim, J.O., Mohapatra, B., Soni, K.S., Luan, H., Williams, S.H., Bielecki, T.A., Feng, D., Storck, M., Band, V., Cohen, S.M., Band, H., Bronich, T.K., Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. J. Control. Release 208 (2015), 59–66.
70. [70] Shin, H.-C., Alani, A.W.G., Rao, D.A., Rockich, N.C., Kwon, G.S., Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Release 140:3 (2009), 294–300.
71. [71] Zhang, X., Zhang, T., Ye, Y., Chen, H., Sun, H., Zhou, X., Ma, Z., Wu, B., Phospholipid-stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect. Eur. J. Pharm. Biopharm. 94 (2015), 30–41.
72. [72] Kim, S.J., Ramsey, D.M., Boyer, C., Davis, T.P., McAlpine, S.R., Effectively delivering a unique Hsp90 inhibitor using star polymers. ACS Med. Chem. Lett. 4:10 (2013), 915–920.
73. [73] Lu, X., Xiao, L., Wang, L., Ruden, D.M., Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem. Pharmacol. 83:8 (2012), 995–1004.
74. [74] Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M.E., Sugarman, S., Ma, W., Patil, S., Norton, L., Hannah, A.L., Hudis, C., HSP90 inhibition is effective in breast cancer: a phase II trial of Tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17:15 (2011), 5132–5139.
75. [75] Pathak, R.K., Dhar, S., A nanoparticle cocktail: temporal release of predefined drug combinations. J. Am. Chem. Soc. 137:26 (2015), 8324–8327.
76. [76] Lee, J.H., Nan, A., Combination drug delivery approaches in metastatic breast cancer. J. Drug Deliv. 2012 (2012), 1–17.
77. [77] Yusuf, R.Z., Duan, Z., Lamendola, D.E., Penson, R.T., Seiden, M.V., Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 3:1 (2003), 1–19.
78. [78] Subbarao Sreedhar, A., Kalmár, É., Csermely, P., Shen, Y.-F., Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 562:1–3 (2004), 11–15.
79. [79] Ogata, M., Naito, Z., Tanaka, S., Moriyama, Y., Asano, G., Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J. Nippon Med. Sch. 67:3 (2000), 177–185.
80. [80] Varkouhi, A.K., Scholte, M., Storm, G., Haisma, H.J., Endosomal escape pathways for delivery of biologicals. J. Control. Release 151:3 (2011), 220–228.
81. [81] Vasir, J.K., Labhasetwar, V., Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59:8 (2007), 718–728.
82. [82] Breunig, M., Bauer, S., Goepferich, A., Polymers and nanoparticles: intelligent tools for intracellular targeting?. Eur. J. Pharm. Biopharm. 68:1 (2008), 112–128.
83. [83] Altieri, D.C., Stein, G.S., Lian, J.B., Languino, L.R., TRAP-1, the mitochondrial Hsp90. Biochim. Biophys. Acta (BBA) - Mol. Cell Res. 1823:3 (2012), 767–773.
84. [84] Yoshida, S., Tsutsumi, S., Muhlebach, G., Sourbier, C., Lee, M.-J., Lee, S., Vartholomaiou, E., Tatokoro, M., Beebe, K., Miyajima, N., Mohney, R.P., Chen, Y., Hasumi, H., Xu, W., Fukushima, H., Nakamura, K., Koga, F., Kihara, K., Trepel, J., Picard, D., Neckers, L., Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc. Natl. Acad. Sci., 201220659, 2013.
85. [85] Kang, B.H., Plescia, J., Dohi, T., Rosa, J., Doxsey, S.J., Altieri, D.C., Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131:2 (2007), 257–270.
86. [86] Kang, B.H., Plescia, J., Song, H.Y., Meli, M., Colombo, G., Beebe, K., Scroggins, B., Neckers, L., Altieri, D.C., Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 119:3 (2009), 454–464.
87. [87] Lee, C., Park, H.-K., Jeong, H., Lim, J., Lee, A.-J., Cheon, K.Y., Kim, C.-S., Thomas, A.P., Bae, B., Kim, N.D., Kim, S.H., Suh, P.-G., Ryu, J.-H., Kang, B.H., Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1. J. Am. Chem. Soc. 137:13 (2015), 4358–4367.
88. [88] Weissig, V., Boddapati, S.V., Jabr, L., D'Souza, G.G., Mitochondria-specific nanotechnology. Nanomedicine 2:3 (2007), 275–285.
89. [89] Weissig, V., Torchilin, V.P., Mitochondriotropic cationic vesicles: a strategy towards mitochondrial Gene therapy. Curr. Pharm. Biotechnol. 1:4 (2000), 325–346.
90. [90] Weissig, V., Torchilin, V.P., Towards mitochondrial gene therapy: DQAsomes as a strategy. J. Drug Target. 9:1 (2001), 1–13.
91. [91] Weissig, V., Lasch, J., Erdos, G., Meyer, H.W., Rowe, T.C., Hughes, J., DQAsomes: a novel potential drug and gene delivery system made from Dequalinium™. Pharm. Res. 15:2 (1998), 334–337.
92. [92] Sheu, S.-S., Nauduri, D., Anders, M.W., Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta (BBA)—Mol. Basis Dis. 1762:2 (2006), 256–265.
93. [93] Adlam, V.J., Harrison, J.C., Porteous, C.M., James, A.M., Smith, R.A.J., Murphy, M.P., Sammut, I.A., Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 19:9 (2005), 1088–1095.
94. [94] Biswas, S., Dodwadkar, N.S., Deshpande, P.P., Torchilin, V.P., Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J. Control. Release 159:3 (2012), 393–402.
95. [95] Marrache, S., Dhar, S., Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl. Acad. Sci. 109:40 (2012), 16288–16293.
96. [96] Yamada, Y., Furukawa, R., Yasuzaki, Y., Harashima, H., Dual function MITO-porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol. Ther. 19:8 (2011), 1449–1456.
97. [97] Chen, X., Ding, Y., Liu, C.-G., Mikhail, S., Yang, C.S., Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Carcinogenesis 23:1 (2002), 123–130.
98. [98] Zheng, H., Takahashi, H., Li, X., Hara, T., Masuda, S., Guan, Y., Takano, Y., Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum. Pathol. 39:7 (2008), 1042–1049.
99. [99] Dejeans, N., Glorieux, C., Guenin, S., Beck, R., Sid, B., Rousseau, R., Bisig, B., Delvenne, P., Buc Calderon, P., Verrax, J., Overexpression of GRP94 in breast cancer cells resistant to oxidative stress promotes high levels of cancer cell proliferation and migration: implications for tumor recurrence. Free Radic. Biol. Med. 52:6 (2012), 993–1002.
100. [100] Tekle, C., van Deurs, B., Sandvig, K., Iversen, T.-G., Cellular trafficking of quantum dot-ligand bioconjugates and their induction of changes in normal routing of unconjugated ligands. Nano Lett. 8:7 (2008), 1858–1865.
101. [101] Wang, G., Norton, A.S., Pokharel, D., Song, Y., Hill, R.A., KDEL peptide gold NAnoconstructs: promising nanoplatforms for drug delivery. Nanomed. Nanotechnol. Biol. Med. 9:3 (2013), 366–374.
102. [102] van der Zee, J., Heating the patient: a promising approach?. Ann. Oncol. 13:8 (2002), 1173–1184.
103. [103] Mosser, D.D., Caron, A.W., Bourget, L., Meriin, A.B., Sherman, M.Y., Morimoto, R.I., Massie, B., The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol. Cell. Biol. 20:19 (2000), 7146–7159.
104. [104] Yavelsky, V., Vais, O., Piura, B., Wolfson, M., Rabinovich, A., Fraifeld, V., The role of Hsp90 in cell response to hyperthermia. J. Therm. Biol. 29:7–8 (2004), 509–514.
105. [105] Cui, X., Yu, Z., Wang, W., Zheng, Y., Liu, W., Li, L., Co-inhibition of HSP70/HSP90 synergistically sensitizes nasopharyngeal carcinoma cells to thermotherapy. Integr. Cancer Ther. 11:1 (2012), 61–67.
106. [106] Chilkoti, A., Dreher, M.R., Meyer, D.E., Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery. Adv. Drug Deliv. Rev. 54:8 (2002), 1093–1111.
107. [107] Bae, Y., Buresh, R.A., Williamson, T.P., Chen, T.-H.H., Furgeson, D.Y., Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin. J. Control. Release 122:1 (2007), 16–23.
108. [108] Rochani, A.K., Ravindran Girija, A., Borah, A., Maekawa, T., Sakthi Kumar, D., Heat-shock protein 90-targeted nano anticancer therapy. J. Pharm. Sci. 105:4 (2016), 1454–1466.
109. [109] Li, Y., Zhang, T., Schwartz, S.J., Sun, D., Sulforaphane potentiates the efficacy of 17-Allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. Nutr. Cancer, 63(7), 2011.
110. [110] Wang, Y., McAlpine, S.R., N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. Chem. Commun. Camb. Engl., 2014.
111. [111] Buckton, L.K., Wang, Y., McConnell, J.R., McAlpine, S.R., Evaluating dual Hsp90 and Hsp70 inhibition as a cancer therapy. Topics in Medicinal Chemistry, 2015, Springer, Berlin Heidelberg, 1–26.
112. [112] Zhang, T., Hamza, A., Cao, X., Wang, B., Yu, S., Zhan, C.-G., Sun, D., A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7:1 (2008), 162–170.
113. [113] Matokanovic, M., Barisic, K., Filipovic-Grcic, J., Maysinger, D., Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90. Eur. J. Pharm. Sci. 50:1 (2013), 149–158.
114. [114] Nishiyama, N., Nori, A., Malugin, A., Kasuya, Y., Kopecková, P., Kopecek, J., Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Res. 63:22 (2003), 7876–7882.
115. [115] Ito, A., Shinkai, M., Honda, H., Wakabayashi, T., Yoshida, J., Kobayashi, T., Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol. Immunother. 50:10 (2001), 515–522.
116. [116] Udono, H., Heat shock protein magic in antigen trafficking within dendritic cells: implications in antigen cross-presentation in immunity. Acta Med. Okayama 66:1 (2012), 1–6.
117. [117] Ciocca, D.R., Cayado-Gutierrez, N., Maccioni, M., Cuello-Carrion, F.D., Heat shock proteins (HSPs) based anti-cancer vaccines. Curr. Mol. Med. 12:9 (2012), 1183–1197.
118. [118] Tosti, G., Cocorocchio, E., Pennacchioli, E., Ferrucci, P.F., Testori, A., Martinoli, C., Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert. Opin. Biol. Ther. 14:7 (2014), 955–967.
119. [119] Ito, A., Honda, H., Kobayashi, T., Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression. Cancer Immunol. Immunother. 55:3 (2006), 320–328.
120. [120] Ito, A., Shinkai, M., Honda, H., Yoshikawa, K., Saga, S., Wakabayashi, T., Yoshida, J., Kobayashi, T., Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol. Immunother. 52:2 (2003), 80–88.
121. [121] Basu, S., Binder, R.J., Suto, R., Anderson, K.M., Srivastava, P.K., Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12:11 (2000), 1539–1546.
122. [122] Shevtsov, M.A., Pozdnyakov, A.V., Mikhrina, A.L., Yakovleva, L.Y., Nikolaev, B.P., Dobrodumov, A.V., Komarova, E.Y., Meshalkina, D.A., Ischenko, A.M., Pitkin, E., Guzhova, I.V., Margulis, B.A., Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70. Int. J. Cancer 135:9 (2014), 2118–2128.
123. [123] Shevtsov, M.A., Komarova, E.Y., Meshalkina, D.A., Bychkova, N.V., Aksenov, N.D., Abkin, S.V., Margulis, B.A., Guzhova, I.V., Exogenously delivered heat shock protein 70 displaces its endogenous analogue and sensitizes cancer cells to lymphocytes-mediated cytotoxicity. Oncotarget 5:10 (2014), 3101–3114.
124. [124] Zhu, R., Zhu, Y., Zhang, M., Xiao, Y., Du, X., Liu, H., Wang, S., The induction of maturation on dendritic cells by TiO2 and Fe(3)O(4)@TiO(2) nanoparticles via NF-κB signaling pathway. Mater. Sci. Eng. C Mater. Biol. Appl. 39 (2014), 305–314.
125. [125] Shevtsov, M.A., Nikolaev, B.P., Yakovleva, L.Y., Parr, M.A., Marchenko, Y.Y., Eliseev, I., Yudenko, A., Dobrodumov, A.V., Zlobina, O., Zhakhov, A., Ischenko, A.M., Pitkin, E., Multhoff, G., 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. J. Control. Release 220:Part A (2015), 329–340.